Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it. - 2South Carolina's measles outbreak reaches 434 cases
- 3Figure out How to Assess the Unwavering quality of SUVs for Seniors
- 4Figure out How to Use Your Nursing Abilities for Better Compensation
- 5Flourishing in Retirement: Individual Accounts of Post-Vocation Satisfaction
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- From Exemplary to Current: Famous Rings Available
- 6 Home Cleaning Administrations to Keep Your Home Unblemished
- Instructions to Expand Your Advantages from an Open Record Reward
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- What to know about Jack Dorsey's new Vine revival, DiVine
- 6 Arranging Administrations to Change Your Open air Space
- Conquering Language Boundaries: Individual Accounts of Multilingualism
